Actively Recruiting
Evaluating AZD4045 CAR-T Therapy Alone and With Daratumumab and Aldesleukin for Adults With Relapsed or Refractory Multiple Myeloma
Led by AstraZeneca · Updated on 2026-10-15
101
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating AZD4045, an allogeneic CAR-T therapy targeting B Cell Maturation Antigen BCMA, for adults with relapsed or refractory multiple myeloma RRMM. This Phase III modular study aims to assess the safety, tolerability, preliminary efficacy, and cellular kinetics of AZD4045 alone and in combination with daratumumab and aldesleukin. The goal is also to determine the recommended dose for Phase 2 treatment. The study includes two treatment modules AZD4045 as a monotherapy and AZD4045 combined with daratumumab and aldesleukin. Participants receive these therapies under medical supervision, with dosing designed to evaluate safety and effectiveness over time. Both modules are conducted in parallel to compare outcomes and cellular behavior. During the trial, participants will undergo regular monitoring for adverse events, dose-limiting toxicities, and treatment responses through clinical evaluations and laboratory tests. Researchers will measure objective and complete response rates, duration and time to response, and track CAR transgene levels and other cellular kinetics parameters for up to two years. Safety and efficacy data will be collected throughout the study period, which may last several years.
CONDITIONS
Brief Title
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here